Sugi Predict

Sugi Predict / Compounds / SCHEMBL7917484

SCHEMBL7917484

SCHEMBL7917484

C[C@H](COS(C)(=O)=O)NC(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.52
▸ CA12 O43570 2/20 0.52
▸ CA1 P00915 2/20 0.52
▸ CA9 Q16790 2/20 0.52
▸ ATM Q13315 1/20 0.52
▸ ELANE P08246 1/20 0.52
▸ CTSK P43235 5/20 0.50
▸ CTRB1 P17538 2/20 0.49
▸ CA5A P35218 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ CTSS P25774 5/20 0.48
▸ CTSL P07711 4/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ CTSB P07858 2/20 0.47
▸ SYK P43405 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2550712 1.00 CA2 (0.52) CA2CA12CA1CA9ATM
SCHEMBL2550717 1.00 CA2 (0.52) CA2CA12CA1CA9ATM
SCHEMBL23000174 0.87 CA2 (0.50) CA2CA12CA1CA9ATM
SCHEMBL20553378 0.87 CA2 (0.50) CA2CA12CA1CA9ATM
SCHEMBL4972907 0.85 CTSK (0.52) CTSKCTSSCTSLCTSB
SCHEMBL4972916 0.85 CTSK (0.52) CTSKCTSSCTSLCTSB
SCHEMBL2726570 0.85 CTSK (0.55) CA1CTSKCTRB1CA5ACTSS
SCHEMBL27645605 0.85 ELANE (0.48) CA2CA12CA1CA9ATM
SCHEMBL7342332 0.84 CTRB1 (0.64) CA2CA12CA1CA9ATM
SCHEMBL7367948 0.84 CTRB1 (0.64) CA2CA12CA1CA9ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092038-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CORBUS PHARMACEUTICALS INC (US) 2026-04-02 — — US disclosed
US-20250248973-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CORBUS PHARMACEUTICALS, INC. 2025-08-07 — — US disclosed
EP-4504179-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF Corbus Pharmaceuticals, Inc. (US) 2025-02-12 — — EP disclosed
WO-2023196556-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CORBUS PHARMACEUTICALS, INC. (US) 2023-10-12 — — WO disclosed
WO-2023196556-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CORBUS PHARMACEUTICALS, INC. (US) 2023-10-12 — — WO disclosed
EP-2657227-B1 NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-04-27 — — EP disclosed
EP-2657227-B1 NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-04-27 — — EP disclosed
US-8883792-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2014-11-11 — — US disclosed
US-8883792-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2014-11-11 — — US disclosed
EP-2657227-A1 NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2013-10-30 — — EP disclosed
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 — — US disclosed
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 — — US disclosed
WO-2008068171-A9 SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS HOFFMANN LA ROCHE (CH) 2009-07-16 — — WO disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 — — US disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 — — US disclosed
WO-2008068171-A1 SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 — — WO disclosed
US-6214829-B1 NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 2001-04-10 — — US disclosed
EP-0900792-A1 Piperazine and piperidine derivatives as 5-HT1 receptor agonists DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1999-03-10 — — EP disclosed
EP-0883613-A1 SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1998-12-16 — — EP disclosed
WO-1997029097-A1 SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1997-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250248973-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CNR1, CNR2, GPR119 CA2 4564/4885CA12 4522/4885CA1 4654/4885
US-20080146565-A1 JNK modulators MAPKAPK2, MAPKAPK3, MAP3K10 CA2 4814/4885CA12 4864/4885CA1 4701/4885
US-20260092038-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CNR1, CNR2, GPR119 CA2 2809/4885CA12 4226/4885CA1 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.